A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 688-692

  Landry, Marie L ^a,q   Stanat, Sylvia ^b   Biron, Karen ^b   Brambilla, Donald ^c   Britt, William ^d   Jokela, Janet ^e   Chou, Sunwen ^f   Drew, W Lawrence ^g   Erice, Alejo ^h   Gilliam, Bruce ⁱ   Lurain, Nell ^j   Manischewitz, Jody ^k   Miner, Richard ^g   Nokta, Mostafa ^l   Reichelderfer, Patricia ^m   Spector, Stephen ⁿ   Weinberg, Adriana ^o   Yen Lieberman, Belinda ^p   Crumpacker, Clyde ^e  

^a YALE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e HARVARD UNIVERSITY   (United States)

^f UNIVERSITY OF OREGON   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j RUSH MEDICAL COLLEGE   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

^l UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF COLORADO   (United States)

^p LERNER RESEARCH INSTITUTE   (United States)

^q YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ARTICLE; CYTOMEGALOVIRUS; DRUG SENSITIVITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IC 50; PHENOTYPE; PRIORITY JOURNAL; STANDARDIZATION; VIRUS ISOLATION; VIRUS PLAQUE;

ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FIBROBLASTS; FOSCARNET; GANCICLOVIR; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS; PLAQUE ASSAY; REPRODUCIBILITY OF RESULTS;

EID: 0033996648     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.688-692.2000     Document Type: Article

References (13)

1. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
2. Chou, T. C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In D. C. Rideout and T. C. Chou (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
3. Drew, W. L., R. C. Miner, D. F. Busch, S. E. Follansbee, J. Gullett, S. G. Mehalko, S. M. Gordon, W. F. Owen, Jr., T. R. Matthews, W. C. Buhles, and B. DeArmond. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719.
4. Erice, A., S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, Jr., and M. C. Jordan. 1989. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293.
5. Erice, A., C. Gil-Roda, J.-L. Perez, H. H. Balfour, Jr., K. J. Sannerud, M. N. Hanson, G. Boivin, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092.
6. Gerna, G., F. Baldanti, M. Zavattoni, A. Sarasini, E. Percivalle, and M. G. Revello. 1992. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Res. 19:333-345.
7. Hanson, M. N., L. C. Preheim, S. Chou, C. L. Talrico, K. K. Biron, and A. Erice. 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39:1204-1205.
8. Jacobson, M. A., W. L. Drew, J. Feinberg, J. J. O'Donnell, P. V. Whitmore, R. D. Miner, and D. Parenti. 1991. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J. Infect. Dis. 163:1348-1351.
9. Knox, K. K., W. R. Drobyski, and D. R. Carrigan. 1991. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337:1292-1293.
10. Leport, C., S. Puget, J. M. Pepin, S. Levy, C. Perronne, F. Brun-Vezinet, and J. L. Vilde. 1993. Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J. Infect. Dis. 168:1329-1330.
11. Stanat, S. C., J. E. Reardon, A. Erice, M. C. Jordan, W. L. Drew, and K. K. Biron. 1991. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35:2191-2197.
12. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
13. Wentworth, B. B., and L. French. 1970. Plaque assay of cytomegalovirus strains of human origin. Proc. Soc. Exp. Biol. Med. 135:253-258.